{"nctId":"NCT01376778","briefTitle":"A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)","startDateStruct":{"date":"2012-04"},"conditions":["Congenital Cytomegalovirus Infection","Maternal Cytomegalovirus Infection"],"count":399,"armGroups":[{"label":"CMV hyperimmune globulin - Cytogam®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: CMV hyperimmune globulin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"CMV hyperimmune globulin","otherNames":["CMV-IGIV","Cytogam"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of primary maternal CMV infection on the basis of one of the following:\n\n  1. A positive CMV Immunoglobulin M (IgM) antibody and low-avidity maternal CMV Immunoglobulin G (IgG) antibody screen\n  2. Evidence of maternal seroconversion with development of CMV IgG antibody following a prior negative CMV screen\n* Gestational age at randomization no later than 23 weeks 6 days based on clinical information and evaluation of the earliest ultrasound; or no later than 27 weeks 6 days for women with a positive IgM, negative IgG initially screened before 23 weeks who are rescreened after 2-4 weeks and have evidence of IgG seroconversion.\n* Singleton pregnancy. A twin pregnancy reduced to singleton (either spontaneously or therapeutically) before 14 weeks by project gestational age is acceptable.\n\nExclusion Criteria:\n\n* Maternal CMV infection pre-dating pregnancy as defined by a high IgG avidity index or a positive IgG in the presence of a negative IgM.\n* Known hypersensitivity to plasma or plasma derived products\n* Planned termination of pregnancy\n* Known major fetal anomalies or demise\n* Maternal Immunoglobulin A (IgA) deficiency\n* Planned use of immune globulin, ganciclovir, or valganciclovir\n* Maternal renal disease (most recent pre-randomization serum creatinine ≥ 1.4 mg/dL; all women must have serum creatinine measured during the pregnancy and prior to randomization)\n* Maternal immune impairment (e.g., HIV infection, organ transplant on anti-rejection medications)\n* Findings on pre-randomization ultrasound suggestive of established fetal CMV infection (cerebral ventriculomegaly, microcephaly, cerebral or intra-abdominal calcifications, abnormalities of amniotic fluid volume, echogenic bowel or ascites). Abnormally low amniotic fluid volume is defined as no fluid prior to 14 weeks or maximum vertical pocket \\< 2 cm on or after 14 weeks gestation. Abnormally high amniotic fluid volume is defined as \\> 10 cm.\n* Positive fetal CMV findings from culture (amniotic fluid) or PCR.\n* Congenital infection with rubella, syphilis, varicella, parvovirus or toxoplasmosis diagnosed by serology and ultrasound or amniotic fluid testing.\n* Intention of the patient or of the managing obstetricians for the delivery to be outside a Maternal-Fetal Medicine Units Network (MFMU) Network center\n* Participation in another interventional study that influences fetal or neonatal death\n* Unwilling or unable to commit to 2 year follow-up of the infant","healthyVolunteers":true,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With the Composite Primary Outcome","description":"The primary outcome is a binary outcome defined by the occurrence or non-occurrence of any of the following vs. none of the following: fetal loss (spontaneous or termination), confirmed fetal CMV infection from amniocentesis, neonatal death before assessment of CMV infection can be made, or neonatal congenital CMV infection. Neonatal congenital CMV infection is diagnosed by urine or saliva collected by 3 weeks of age that is positive for CMV by culture (the intent will be to obtain in the first two days of life). In the event that Polymerase Chain Reaction (PCR) is positive but culture is negative, a repeat culture must be positive by 3 weeks of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Had a Fetus or Neonate With CMV Infection","description":"Component of composite primary outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Had a Neonatal Death Without CMV Infection","description":"component of composite primary outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With a Fetal or Neonatal Death With Proven CMV Infection","description":"component of primary composite outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Fetal Death Without Proven CMV Infection","description":"component of primary composite outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Gestational Hypertension or Preeclampsia","description":"Gestational hypertension or preeclampsia is a binary outcome defined by occurrence or non-occurrence of gestational hypertension or preeclampsia. Gestational hypertension or preeclampsia are new onset hypertension during pregnancy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Placental Abruption","description":"Placental abruption is a binary outcome defined by occurrence or non-occurrence of placental abruption, defined as bleeding and contraction pain","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Gestational Age at Delivery","description":"Gestational age at delivery in weeks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","spread":"4.1"},{"groupId":"OG001","value":"38.6","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Whose Gestational Age at Delivery Was Before 37 Weeks","description":"Gestational age before 37 weeks gestation is a binary outcome meaning occurrence or non-occurrence of delivery before 37 weeks gestation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Whose Gestational Age at Delivery Was Before 34 Weeks, 0 Days","description":"Gestational age before 34 weeks, 0 days gestation is a binary outcome meaning occurrence or non-occurrence of delivery before 34 weeks gestation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Yes or no to Medication Side Effects","description":"Occurrence or non-occurrence of a designated side effect of medication","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"131","spread":null}]},{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Had a Fetal or Neonatal Death","description":"Fetal death or death of a neonate born alive","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Neonatal Head Circumference","description":"Neonatal head circumference measured within 72 hours of birth","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":"2.1"},{"groupId":"OG001","value":"34.1","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Median Birth Weight","description":"Birth weight as recorded in the medical record","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3268","spread":"657"},{"groupId":"OG001","value":"3303","spread":"548"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Fetal Growth Restriction","description":"Fetal growth restriction is a binary outcome defined as the occurrence or non-occurrence of growth restriction (defined as \\<5th percentile weight for gestational age, assessed specifically by sex and race of the infant based on United States birth certificate data)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Symptomatic CMV Infection","description":"Fetal or neonatal symptomatic CMV infection is a binary outcome defined as the occurrence or non-occurrence of symptomatic CMV infection defined as CMV isolated from an amniocentesis, or urine or saliva during the first three weeks of life and at least one of the following: jaundice (with direct bilirubin exceeding 20% of total bilirubin), thrombocytopenia , anemia , hepatitis, hepatomegaly, splenomegaly, growth restriction, failure to thrive, intracerebral calcifications, microcephaly, hypotonia, seizures, petechial rash, hearing loss, interstitial pneumonitis, thrombocytopenia, anemia, hepatitis, chorioretinitis, or CMV in cerebrospinal fluid","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Neonates With Grade 3 or 4 Intraventricular Hemorrhage","description":"Intraventricular hemorrhage (IVH) as determined by cranial ultrasounds performed as part of routine clinical care and classified based on the Papile classification system. IVH is a binary outcome defined by occurrence or non-occurrence of IVH","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Neonates With Ventriculomegaly","description":"Ventriculomegaly is a binary outcome defined by the occurrence or non-occurrence of ventriculomegaly","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Neonates With Retinopathy of Prematurity (ROP)","description":"Retinopathy of prematurity is a binary outcome defined by the occurrence or non-occurrence of retinopathy of prematurity, diagnosed by ophthalmologic examination of the retina and a diagnosis of Stage I (demarcation line in the retina) or greater.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Neonates With Respiratory Distress Syndrome","description":"Respiratory distress syndrome is a binary outcome defined by the occurrence or non-occurrence of Respiratory distress syndrome (defined as the presence of clinical signs of respiratory distress (tachypnea, retractions, flaring, grunting, or cyanosis), with an oxygen requirement and a chest x-ray that shows hypoventilation and reticulogranular infiltrates).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Neonates With Chronic Lung Disease","description":"Neonatal chronic lung disease is a binary outcome defined by the occurrence or non-occurrence of chronic lung disease or bronchopulmonary dysplasia (BPD) defined as oxygen requirement at 28 days of life","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Neonates With Necrotizing Enterocolitis (NEC)","description":"Necrotizing enterocolitis (NEC) is a binary outcome defined by the occurrence or non-occurrence of NEC, defined as modified Bell Stage 2 or 3. Stage 2: Clinical signs and symptoms with pneumatosis intestinalis on radiographs. Stage 3: Advanced clinical signs and symptoms, pneumatosis, impending or proven intestinal perforation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Neonates With Hyperbilirubinemia","description":"Hyperbilirubinemia is a binary outcome defined by the occurrence or non-occurrence of hyperbilirubinemia. Peak total bilirubin of at least 15 mg% or the use of phototherapy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Neonates With Suspected Neonatal Sepsis","description":"Suspected neonatal sepsis is a binary outcome defined as the occurrence or non-occurrence of suspected neonatal sepsis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Neonates With Neonatal Pneumonia","description":"Neonatal pneumonia is a binary outcome defined as the occurrence or non-occurrence of neonatal pneumonia","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Neonates Experiencing Seizures / Encephalopathy","description":"Neonatal seizures/encephalopathy is a binary outcome defined as the occurrence or non-occurrence of seizures/encephalopathy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Length of Neonatal Hospital Stay","description":"Length of hospital stay, need for Neonatal Intensive Care Unit (NICU) or intermediate care admission and length of stay if admitted","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Infant or Child Death","description":"Death of infant or child before the 24 month study exam","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Children With Sensorineural Hearing Loss","description":"Sensorineural hearing loss is defined as the occurrence or non-occurrence of sensorineural hearing loss defined as unilateral and bilateral sensorineural hearing loss","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Children Diagnosed With Chorioretinitis","description":"Chorioretinitis is defined as the occurrence or non-occurrence of chorioretinitis defined by ophthalmologic exam","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Cognitive Composite Scores From the Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)","description":"The Bayley Scales of Infant and Toddler Development® \\| Third Edition (Bayley®-III), is a comprehensive tool to identify development issues during early childhood. The Bayley-III Cognitive Scale subtests assess cognitive function through the use of memory, problem solving and manipulation subtests. Scores on individual Cognitive subtests range from 1 (worst outcome) to 19 (better outcome) (Mean 10, SD 3). Individual subtest scores between 8 and 12 are considered average. The raw scores on the subtests are converted to scaled scores based on American norms by age. Cognitive Scale composite scores range from 55 (low, worse outcome) to 155 (high, better outcome) (mean 100; SD 15). Severe disability was defined as a composite score \\<70.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":"15.1"},{"groupId":"OG001","value":"97.1","spread":"13.5"}]}]}]},{"type":"SECONDARY","title":"Mean Motor Composite Scores From the Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)","description":"The Bayley Scales of Infant and Toddler Development® \\| Third Edition (Bayley®-III), is a comprehensive tool to identify development issues during early childhood. The Bayley-III Motor Scale subtests assess motor function through fine motor and gross motor subtests. Scores on individual Motor subtests range from 1 (worst outcome) to 19 (better outcome) (Mean 10, SD 3). Individual subtest scores between 8 and 12 are considered average. The raw scores on the subtests are converted to scaled scores based on American norms by age. Motor Scale composite scores range from 55 (low, worse outcome) to 155 (high, better outcome) (mean 100; SD 15). Severe disability was defined as a composite score \\<70.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":"16.4"},{"groupId":"OG001","value":"101.9","spread":"14.9"}]}]}]},{"type":"SECONDARY","title":"Number of Infants or Children With the Composite Outcome","description":"Composite outcome at 24 months including any of the following attributable to congenital CMV infection: • Sensorineural hearing loss (unilateral and bilateral) • Developmental delay defined as Cognitive score \\< 70 or Motor score \\< 70 on the Bayley III • Chorioretinitis • Fetal loss or death of neonate, infant or child","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Child Status at 24 Months of Age","description":"Child status at age 24 months, classified as: • Fetal loss or death of neonate, infant or child • Congenital CMV infection with severe disability • Congenital CMV infection without severe disability • Infant not infected with CMV","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"19","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]}]},{"type":"SECONDARY","title":"Failure to Thrive at 24 Months","description":"Failure to thrive defined as \\<10th percentile for weight at 24 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":32,"n":206},"commonTop":["congenital anomaly (non-serious)","allergic reaction"]}}}